Carl June (Brian Ach/Getty Images for TIME 100 Health Summit)
February 2, 2022 11:00 AM ESTUpdated 12:00 PM
R&D
Discovery

Carl June: ‘We can now con­clude that CAR-T cells can ac­tu­al­ly cure pa­tients’

Jason Mast

Editor

A decade af­ter the first-ever pa­tients were in­fused with CAR-T, at least two of them re­main can­cer free and their ge­net­i­cal­ly mod­i­fied cells still ap­pear …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times